Details of the Drug

General Information of Drug (ID: DMN6DXL)

Drug Name
Risperidone
Synonyms
Belivon; Risperdal; Risperdone; Risperidal; Risperidona; Risperidonum; Risperin; Rispolept; Rispolin; Sequinan; Risperdal Consta; Risperidona [Spanish]; Risperidonum [Latin]; R 62 766; R 64766; R64766; Consta, Risperdal; KS-1106; R 64,766; R-118; R-64766; R64,766; Risperdal (TN); Risperdal M-Tab; Risperidal M-Tab; Risperidone (RIS); Risperidone, placebo; R 64 766, Risperdal, Risperidone; R-64,766; R-64-766; Risperidone [USAN:BAN:INN]; Risperidone (JAN/USAN/INN); 3-(2-(4-(6-Fluoro-1,2-benzisoxazol-3-yl)piperidino)ethyl)-6,7,8,9-tetrahydro-2-methyl-4H-pyrido(1,2-a)pyrimidin-4-one; 3-[2-[-4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9-tetrahydro-2-methyl-4H-pyrido[1,2-a]pyrimidin-4-one; 3-[2-[4-(6-Fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]-6,7,8,9-tetrahydro-2-methyl-4H-pyrido [1,2-a] pyrimidin-4-one; 3-[2-[4-(6-Fluoro-1,2-benzisoxazol-3-yl)piperi-dino]ethyl]-6,7,8,9-tetrahydro-2-methyl-4H-pyrido[1,2-a]-pyrimidin-4-one; 3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9-tetrahydro-2-methyl-4H-pyrido[1,2-a]pyrimidin-4-one; 3-[2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl]-2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one; 3-{2-[4-(6-Fluoro-benzo[d]isoxazol-3-yl)-piperidin-1-yl]-ethyl}-2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one; 3-{2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)piperidin-1-yl]ethyl}-2-methyl-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-4-one; 3-{2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl}-2-methyl-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-4-one
Indication
Disease Entry ICD 11 Status REF
Schizophrenia 6A20 Approved [1], [2]
Therapeutic Class
Antipsychotic Agents
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 410.5
Topological Polar Surface Area (xlogp) 2.7
Rotatable Bond Count (rotbonds) 4
Hydrogen Bond Donor Count (hbonddonor) 0
Hydrogen Bond Acceptor Count (hbondacc) 6
ADMET Property
Absorption Cmax
The maximum plasma concentration (Cmax) of drug is 200 mcg/L [3]
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability [4]
Bioavailability
66% of drug becomes completely available to its intended biological destination(s) [5]
Clearance
The clearance of drug is 15-59 mL/min [6]
Elimination
3% of drug is excreted from urine in the unchanged form [4]
Half-life
The concentration or amount of drug in body reduced by one-half in 3 hours [7]
Metabolism
The drug is metabolized via the hepatic cytochrome P450 2D6 isozyme to 9-hydroxyrisperidone [8]
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 0.555 micromolar/kg/day [9]
Unbound Fraction
The unbound fraction of drug in plasma is 0.1% [10]
Vd
The volume of distribution (Vd) of drug is 1-2 L/kg [11]
Water Solubility
The ability of drug to dissolve in water is measured as 0.25 mg/mL [4]
Chemical Identifiers
Formula
C23H27FN4O2
IUPAC Name
3-[2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl]-2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one
Canonical SMILES
CC1=C(C(=O)N2CCCCC2=N1)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F
InChI
InChI=1S/C23H27FN4O2/c1-15-18(23(29)28-10-3-2-4-21(28)25-15)9-13-27-11-7-16(8-12-27)22-19-6-5-17(24)14-20(19)30-26-22/h5-6,14,16H,2-4,7-13H2,1H3
InChIKey
RAPZEAPATHNIPO-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
5073
ChEBI ID
CHEBI:8871
DrugBank ID
DB00734
TTD ID
D01AZG
VARIDT ID
DR00384
INTEDE ID
DR1428
ACDINA ID
D00599

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Dopamine D2 receptor (D2R) TTEX248 DRD2_HUMAN Antagonist [12], [13]

Drug Transporter (DTP)
DTP Name DTP ID UniProt ID MOA REF
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [14]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Substrate [15]
Cytochrome P450 2D6 (CYP2D6)
Main DME 		DECB0K3 CP2D6_HUMAN Substrate [16]
Cytochrome P450 3A5 (CYP3A5) DEIBDNY CP3A5_HUMAN Substrate [17]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Schizophrenia
ICD Disease Classification 6A20
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Dopamine D2 receptor (D2R) DTT DRD2 2.50E-02 -0.08 -0.49
P-glycoprotein 1 (ABCB1) DTP P-GP 9.39E-02 1.07E-01 2.80E-01
Cytochrome P450 3A5 (CYP3A5) DME CYP3A5 9.96E-01 -3.17E-03 -1.84E-02
Cytochrome P450 2D6 (CYP2D6) DME CYP2D6 7.30E-01 -1.91E-02 -1.41E-01
Cytochrome P450 3A4 (CYP3A4) DME CYP3A4 1.04E-02 6.29E-02 3.54E-01
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Risperidone
DDI Drug Name DDI Drug ID Severity Mechanism Disease REF
Mesoridazine DM2ZGAN Major Increased risk of prolong QT interval by the combination of Risperidone and Mesoridazine. Schizophrenia [6A20] [61]
Aripiprazole DM3NUMH Moderate Additive anticholinergic effects by the combination of Risperidone and Aripiprazole. Schizophrenia [6A20] [62]
Iloperidone DM6AUFY Major Increased risk of prolong QT interval by the combination of Risperidone and Iloperidone. Schizophrenia [6A20] [61]
Paliperidone DM7NPJS Moderate Increased risk of prolong QT interval by the combination of Risperidone and Paliperidone. Schizophrenia [6A20] [61]
Molindone DMAH70G Moderate Additive anticholinergic effects by the combination of Risperidone and Molindone. Schizophrenia [6A20] [62]
Thiothixene DMDINC4 Moderate Additive anticholinergic effects by the combination of Risperidone and Thiothixene. Schizophrenia [6A20] [62]
Trifluoperazine DMKBYWI Moderate Additive anticholinergic effects by the combination of Risperidone and Trifluoperazine. Schizophrenia [6A20] [62]
Amisulpride DMSJVAM Major Increased risk of prolong QT interval by the combination of Risperidone and Amisulpride. Schizophrenia [6A20] [63]
Asenapine DMSQZE2 Moderate Increased risk of prolong QT interval by the combination of Risperidone and Asenapine. Schizophrenia [6A20] [61]
Pimozide DMW83TP Major Increased risk of prolong QT interval by the combination of Risperidone and Pimozide. Schizophrenia [6A20] [64]
⏷ Show the Full List of 10 DDI Information of This Drug
Coadministration of a Drug Treating the Disease Different from Risperidone (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Ivosidenib DM8S6T7 Major Increased risk of prolong QT interval by the combination of Risperidone and Ivosidenib. Acute myeloid leukaemia [2A60] [65]
Midostaurin DMI6E0R Moderate Increased risk of prolong QT interval by the combination of Risperidone and Midostaurin. Acute myeloid leukaemia [2A60] [61]
Idarubicin DMM0XGL Moderate Increased risk of prolong QT interval by the combination of Risperidone and Idarubicin. Acute myeloid leukaemia [2A60] [61]
Oliceridine DM6MDCF Major Additive CNS depression effects by the combination of Risperidone and Oliceridine. Acute pain [MG31] [66]
Scopolamine DMOM8AL Moderate Additive anticholinergic effects by the combination of Risperidone and Scopolamine. Addictive disorder [6C50-6C5Z] [62]
Mepyramine DMB4SFH Moderate Additive anticholinergic effects by the combination of Risperidone and Mepyramine. Allergic/hypersensitivity disorder [4A80-4A8Z] [67]
Phenyltoloxamine DMKAEQW Moderate Additive anticholinergic effects by the combination of Risperidone and Phenyltoloxamine. Allergic/hypersensitivity disorder [4A80-4A8Z] [67]
Tripelennamine DMZBU15 Moderate Additive anticholinergic effects by the combination of Risperidone and Tripelennamine. Allergic/hypersensitivity disorder [4A80-4A8Z] [62]
Memantine DMD9WSC Moderate Additive anticholinergic effects by the combination of Risperidone and Memantine. Alzheimer disease [8A20] [62]
Rivastigmine DMG629M Moderate Antagonize the effect of Risperidone when combined with Rivastigmine. Alzheimer disease [8A20] [68]
Donepezil DMIYG7Z Moderate Antagonize the effect of Risperidone when combined with Donepezil. Alzheimer disease [8A20] [68]
Metronidazole DMTIVEN Minor Increased risk of prolong QT interval by the combination of Risperidone and Metronidazole. Amoebiasis [1A36] [69]
Isosorbide dinitrate DMBI4JG Moderate Additive hypotensive effects by the combination of Risperidone and Isosorbide dinitrate. Anal fissure/fistula [DB50] [70]
Ivabradine DM0L594 Major Increased risk of ventricular arrhythmias by the combination of Risperidone and Ivabradine. Angina pectoris [BA40] [64]
Bepridil DM0RKS4 Major Increased risk of prolong QT interval by the combination of Risperidone and Bepridil. Angina pectoris [BA40] [61]
Amyl nitrite DMJKO05 Moderate Additive hypotensive effects by the combination of Risperidone and Amyl nitrite. Angina pectoris [BA40] [70]
Nifedipine DMSVOZT Moderate Additive hypotensive effects by the combination of Risperidone and Nifedipine. Angina pectoris [BA40] [70]
Bedaquiline DM3906J Major Increased risk of prolong QT interval by the combination of Risperidone and Bedaquiline. Antimicrobial drug resistance [MG50-MG52] [71]
Cilostazol DMZMSCT Moderate Increased risk of prolong QT interval by the combination of Risperidone and Cilostazol. Arterial occlusive disease [BD40] [61]
Posaconazole DMUL5EW Moderate Increased risk of prolong QT interval by the combination of Risperidone and Posaconazole. Aspergillosis [1F20] [61]
Levalbuterol DM5YBO1 Moderate Increased risk of prolong QT interval by the combination of Risperidone and Levalbuterol. Asthma [CA23] [72]
Terbutaline DMD4381 Moderate Increased risk of ventricular arrhythmias by the combination of Risperidone and Terbutaline. Asthma [CA23] [73]
Pirbuterol DMI5678 Moderate Increased risk of prolong QT interval by the combination of Risperidone and Pirbuterol. Asthma [CA23] [73]
Salbutamol DMN9CWF Moderate Increased risk of ventricular arrhythmias by the combination of Risperidone and Salbutamol. Asthma [CA23] [72]
Formoterol DMSOURV Moderate Increased risk of ventricular arrhythmias by the combination of Risperidone and Formoterol. Asthma [CA23] [73]
Desipramine DMT2FDC Moderate Additive anticholinergic effects by the combination of Risperidone and Desipramine. Attention deficit hyperactivity disorder [6A05] [62]
Clarithromycin DM4M1SG Moderate Increased risk of prolong QT interval by the combination of Risperidone and Clarithromycin. Bacterial infection [1A00-1C4Z] [61]
Sulfamethoxazole DMB08GE Minor Increased risk of prolong QT interval by the combination of Risperidone and Sulfamethoxazole. Bacterial infection [1A00-1C4Z] [61]
Sparfloxacin DMB4HCT Major Increased risk of prolong QT interval by the combination of Risperidone and Sparfloxacin. Bacterial infection [1A00-1C4Z] [74]
Gemifloxacin DMHT34O Moderate Increased risk of prolong QT interval by the combination of Risperidone and Gemifloxacin. Bacterial infection [1A00-1C4Z] [74]
Norfloxacin DMIZ6W2 Moderate Increased risk of prolong QT interval by the combination of Risperidone and Norfloxacin. Bacterial infection [1A00-1C4Z] [74]
Levofloxacin DMS60RB Moderate Increased risk of prolong QT interval by the combination of Risperidone and Levofloxacin. Bacterial infection [1A00-1C4Z] [74]
Lomefloxacin DMVRH9C Moderate Increased risk of prolong QT interval by the combination of Risperidone and Lomefloxacin. Bacterial infection [1A00-1C4Z] [61]
Telithromycin DMZ4P3A Moderate Increased risk of prolong QT interval by the combination of Risperidone and Telithromycin. Bacterial infection [1A00-1C4Z] [61]
Retigabine DMGNYIH Moderate Increased risk of prolong QT interval by the combination of Risperidone and Retigabine. Behcet disease [4A62] [61]
Loperamide DMOJZQ9 Moderate Additive antimotility effects by the combination of Risperidone and Loperamide. Bowel habit change [ME05] [75]
Eribulin DM1DX4Q Moderate Increased risk of prolong QT interval by the combination of Risperidone and Eribulin. Breast cancer [2C60-2C6Y] [61]
Lapatinib DM3BH1Y Moderate Increased risk of prolong QT interval by the combination of Risperidone and Lapatinib. Breast cancer [2C60-2C6Y] [61]
Acetylcholine DMDF79Z Moderate Antagonize the effect of Risperidone when combined with Acetylcholine. Cataract [9B10] [76]
PF-04449913 DMSB068 Moderate Increased risk of prolong QT interval by the combination of Risperidone and PF-04449913. Chronic myelomonocytic leukaemia [2A40] [77]
Umeclidinium DM4E8O9 Moderate Additive anticholinergic effects by the combination of Risperidone and Umeclidinium. Chronic obstructive pulmonary disease [CA22] [78]
Olodaterol DM62B78 Moderate Increased risk of prolong QT interval by the combination of Risperidone and Olodaterol. Chronic obstructive pulmonary disease [CA22] [73]
Vilanterol DMF5EK1 Moderate Increased risk of ventricular arrhythmias by the combination of Risperidone and Vilanterol. Chronic obstructive pulmonary disease [CA22] [72]
Tiotropium DMFDC0Q Moderate Additive anticholinergic effects by the combination of Risperidone and Tiotropium. Chronic obstructive pulmonary disease [CA22] [78]
Salmeterol DMIEU69 Moderate Increased risk of ventricular arrhythmias by the combination of Risperidone and Salmeterol. Chronic obstructive pulmonary disease [CA22] [73]
Revefenacin DMMP5SI Moderate Additive anticholinergic effects by the combination of Risperidone and Revefenacin. Chronic obstructive pulmonary disease [CA22] [78]
Indacaterol DMQJHR7 Moderate Increased risk of ventricular arrhythmias by the combination of Risperidone and Indacaterol. Chronic obstructive pulmonary disease [CA22] [73]
Arformoterol DMYM974 Moderate Increased risk of ventricular arrhythmias by the combination of Risperidone and Arformoterol. Chronic obstructive pulmonary disease [CA22] [73]
Dihydrocodeine DMB0FWL Major Additive CNS depression effects by the combination of Risperidone and Dihydrocodeine. Chronic pain [MG30] [79]
Isoproterenol DMK7MEY Moderate Increased risk of ventricular arrhythmias by the combination of Risperidone and Isoproterenol. Conduction disorder [BC63] [72]
Olopatadine DMKMWQG Moderate Additive CNS depression effects by the combination of Risperidone and Olopatadine. Conjunctiva disorder [9A60] [80]
Halothane DM80OZ5 Moderate Increased risk of prolong QT interval by the combination of Risperidone and Halothane. Corneal disease [9A76-9A78] [61]
Propofol DMB4OLE Moderate Increased risk of prolong QT interval by the combination of Risperidone and Propofol. Corneal disease [9A76-9A78] [81]
Sevoflurane DMC9O43 Moderate Increased risk of prolong QT interval by the combination of Risperidone and Sevoflurane. Corneal disease [9A76-9A78] [61]
Alfentanil DMVO0UB Major Additive CNS depression effects by the combination of Risperidone and Alfentanil. Corneal disease [9A76-9A78] [66]
Remifentanil DMZTXCH Major Additive CNS depression effects by the combination of Risperidone and Remifentanil. Corneal disease [9A76-9A78] [66]
Probucol DMVZQ2M Moderate Increased risk of prolong QT interval by the combination of Risperidone and Probucol. Coronary atherosclerosis [BA80] [61]
Clofazimine DMEBOFW Moderate Increased risk of prolong QT interval by the combination of Risperidone and Clofazimine. Crohn disease [DD70] [82]
Mifepristone DMGZQEF Major Increased risk of prolong QT interval by the combination of Risperidone and Mifepristone. Cushing syndrome [5A70] [61]
Osilodrostat DMIJC9X Moderate Increased risk of prolong QT interval by the combination of Risperidone and Osilodrostat. Cushing syndrome [5A70] [64]
Ethanol DMDRQZU Moderate Additive CNS depression effects by the combination of Risperidone and Ethanol. Cystitis [GC00] [80]
Cyclandelate DMO0R76 Moderate Additive hypotensive effects by the combination of Risperidone and Cyclandelate. Dementia [6D80-6D8Z] [70]
Escitalopram DMFK9HG Major Increased risk of prolong QT interval by the combination of Risperidone and Escitalopram. Depression [6A70-6A7Z] [61]
OPC-34712 DMHG57U Moderate Additive anticholinergic effects by the combination of Risperidone and OPC-34712. Depression [6A70-6A7Z] [62]
Clomipramine DMINRKW Moderate Additive anticholinergic effects by the combination of Risperidone and Clomipramine. Depression [6A70-6A7Z] [62]
Doxepin DMPI98T Moderate Additive anticholinergic effects by the combination of Risperidone and Doxepin. Depression [6A70-6A7Z] [62]
Maprotiline DMPWB7T Moderate Decreased metabolism of Risperidone caused by Maprotiline mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [83]
Esketamine DMVU687 Moderate Additive CNS depression effects by the combination of Risperidone and Esketamine. Depression [6A70-6A7Z] [69]
Mepenzolate DM8YU2F Moderate Additive anticholinergic effects by the combination of Risperidone and Mepenzolate. Digestive system disease [DE2Z] [62]
Oxybutynine DMJPBAX Moderate Additive anticholinergic effects by the combination of Risperidone and Oxybutynine. Discovery agent [N.A.] [62]
Tetrabenazine DMYWQ0O Major Increased risk of prolong QT interval by the combination of Risperidone and Tetrabenazine. Dissociative neurological symptom disorder [6B60] [84]
Meclizine DMS7T13 Moderate Additive anticholinergic effects by the combination of Risperidone and Meclizine. Dizziness and giddiness [MB48] [62]
Deutetrabenazine DMUPFLI Major Increased risk of prolong QT interval by the combination of Risperidone and Deutetrabenazine. Dystonic disorder [8A02] [85]
Ingrezza DMVPLNC Moderate Increased risk of prolong QT interval by the combination of Risperidone and Ingrezza. Dystonic disorder [8A02] [86]
Zonisamide DM0DTF7 Major Increased risk of hyperpyrexia by the combination of Risperidone and Zonisamide. Epilepsy/seizure [8A61-8A6Z] [87]
Diphenhydramine DMKQTBA Moderate Antagonize the effect of Risperidone when combined with Diphenhydramine. Episodic vestibular syndrome [AB31] [88]
Ethacrynic acid DM60QMR Moderate Increased risk of ventricular arrhythmias by the combination of Risperidone and Ethacrynic acid. Essential hypertension [BA00] [69]
Phenoxybenzamine DM8KSQH Moderate Additive hypotensive effects by the combination of Risperidone and Phenoxybenzamine. Essential hypertension [BA00] [70]
Guanethidine DM9NSWT Moderate Additive hypotensive effects by the combination of Risperidone and Guanethidine. Essential hypertension [BA00] [70]
Nadolol DMW6GVL Moderate Additive hypotensive effects by the combination of Risperidone and Nadolol. Essential hypertension [BA00] [70]
Solifenacin DMG592Q Moderate Increased risk of prolong QT interval by the combination of Risperidone and Solifenacin. Functional bladder disorder [GC50] [61]
Mirabegron DMS1GYT Moderate Decreased metabolism of Risperidone caused by Mirabegron mediated inhibition of CYP450 enzyme. Functional bladder disorder [GC50] [89]
Tolterodine DMSHPW8 Moderate Additive anticholinergic effects by the combination of Risperidone and Tolterodine. Functional bladder disorder [GC50] [62]
Pentamidine DMHZJCG Moderate Increased risk of prolong QT interval by the combination of Risperidone and Pentamidine. Fungal infection [1F29-1F2F] [61]
Terbinafine DMI6HUW Moderate Decreased metabolism of Risperidone caused by Terbinafine mediated inhibition of CYP450 enzyme. Fungal infection [1F29-1F2F] [90]
Ketoconazole DMPZI3Q Moderate Increased risk of prolong QT interval by the combination of Risperidone and Ketoconazole. Fungal infection [1F29-1F2F] [61]
Propantheline DM2EN6G Moderate Additive anticholinergic effects by the combination of Risperidone and Propantheline. Gastric ulcer [DA60] [62]
Sunitinib DMCBJSR Moderate Increased risk of prolong QT interval by the combination of Risperidone and Sunitinib. Gastrointestinal stromal tumour [2B5B] [61]
Acetazolamide DM1AF5U Moderate Increased risk of ventricular arrhythmias by the combination of Risperidone and Acetazolamide. Glaucoma [9C61] [69]
Pilocarpine DMV9ADG Moderate Antagonize the effect of Risperidone when combined with Pilocarpine. Glaucoma [9C61] [76]
Carvedilol DMHTEAO Moderate Additive hypotensive effects by the combination of Risperidone and Carvedilol. Heart failure [BD10-BD1Z] [70]
Chlorothiazide DMLHESP Moderate Increased risk of ventricular arrhythmias by the combination of Risperidone and Chlorothiazide. Heart failure [BD10-BD1Z] [69]
Bumetanide DMRV7H0 Moderate Increased risk of ventricular arrhythmias by the combination of Risperidone and Bumetanide. Heart failure [BD10-BD1Z] [69]
Hydroflumethiazide DMVPUQI Moderate Increased risk of ventricular arrhythmias by the combination of Risperidone and Hydroflumethiazide. Heart failure [BD10-BD1Z] [69]
Fostemsavir DM50ILT Moderate Increased risk of prolong QT interval by the combination of Risperidone and Fostemsavir. Human immunodeficiency virus disease [1C60-1C62] [91]
Cobicistat DM6L4H2 Moderate Decreased clearance of Risperidone due to the transporter inhibition by Cobicistat. Human immunodeficiency virus disease [1C60-1C62] [92]
Saquinavir DMG814N Major Increased risk of prolong QT interval by the combination of Risperidone and Saquinavir. Human immunodeficiency virus disease [1C60-1C62] [93]
Rilpivirine DMJ0QOW Moderate Increased risk of prolong QT interval by the combination of Risperidone and Rilpivirine. Human immunodeficiency virus disease [1C60-1C62] [61]
Isosorbide mononitrate DMYLMU0 Moderate Additive hypotensive effects by the combination of Risperidone and Isosorbide mononitrate. Hydrocephalus [8D64] [70]
Cinacalcet DMCX0K3 Moderate Decreased metabolism of Risperidone caused by Cinacalcet mediated inhibition of CYP450 enzyme. Hyper-parathyroidism [5A51] [69]
Eprosartan DM07K2I Moderate Additive hypotensive effects by the combination of Risperidone and Eprosartan. Hypertension [BA00-BA04] [70]
Acebutolol DM0TI4U Moderate Additive hypotensive effects by the combination of Risperidone and Acebutolol. Hypertension [BA00-BA04] [70]
Captopril DM458UM Moderate Additive hypotensive effects by the combination of Risperidone and Captopril. Hypertension [BA00-BA04] [70]
Penbutolol DM4ES8F Moderate Additive hypotensive effects by the combination of Risperidone and Penbutolol. Hypertension [BA00-BA04] [70]
Methyldopa DM5I621 Moderate Additive hypotensive effects by the combination of Risperidone and Methyldopa. Hypertension [BA00-BA04] [70]
Nebivolol DM7F1PA Moderate Additive hypotensive effects by the combination of Risperidone and Nebivolol. Hypertension [BA00-BA04] [70]
Levamlodipine DM92S6N Moderate Additive hypotensive effects by the combination of Risperidone and Levamlodipine. Hypertension [BA00-BA04] [70]
TAK-491 DMCF6SX Moderate Additive hypotensive effects by the combination of Risperidone and TAK-491. Hypertension [BA00-BA04] [70]
Pindolol DMD2NV7 Moderate Additive hypotensive effects by the combination of Risperidone and Pindolol. Hypertension [BA00-BA04] [70]
Fenoldopam DMFAOKP Moderate Additive hypotensive effects by the combination of Risperidone and Fenoldopam. Hypertension [BA00-BA04] [70]
Indapamide DMGN1PW Moderate Increased risk of ventricular arrhythmias by the combination of Risperidone and Indapamide. Hypertension [BA00-BA04] [69]
Trichlormethiazide DMHAQCO Moderate Increased risk of ventricular arrhythmias by the combination of Risperidone and Trichlormethiazide. Hypertension [BA00-BA04] [69]
Diazoxide DML1538 Moderate Additive hypotensive effects by the combination of Risperidone and Diazoxide. Hypertension [BA00-BA04] [70]
Perindopril DMOPZDT Moderate Additive hypotensive effects by the combination of Risperidone and Perindopril. Hypertension [BA00-BA04] [70]
Felodipine DMOSW35 Moderate Additive hypotensive effects by the combination of Risperidone and Felodipine. Hypertension [BA00-BA04] [70]
Quinapril DMR8H31 Moderate Additive hypotensive effects by the combination of Risperidone and Quinapril. Hypertension [BA00-BA04] [70]
Deserpidine DMRH7CV Moderate Additive hypotensive effects by the combination of Risperidone and Deserpidine. Hypertension [BA00-BA04] [70]
Telmisartan DMS3GX2 Moderate Additive hypotensive effects by the combination of Risperidone and Telmisartan. Hypertension [BA00-BA04] [70]
Irbesartan DMTP1DC Moderate Additive hypotensive effects by the combination of Risperidone and Irbesartan. Hypertension [BA00-BA04] [70]
Hydralazine DMU8JGH Moderate Additive hypotensive effects by the combination of Risperidone and Hydralazine. Hypertension [BA00-BA04] [70]
Hydrochlorothiazide DMUSZHD Moderate Increased risk of ventricular arrhythmias by the combination of Risperidone and Hydrochlorothiazide. Hypertension [BA00-BA04] [69]
Clevidipine butyrate DMW4M97 Moderate Additive hypotensive effects by the combination of Risperidone and Clevidipine butyrate. Hypertension [BA00-BA04] [70]
Givosiran DM5PFIJ Moderate Decreased metabolism of Risperidone caused by Givosiran mediated inhibition of CYP450 enzyme. Inborn porphyrin/heme metabolism error [5C58] [94]
Belladonna DM2RBWK Moderate Additive anticholinergic effects by the combination of Risperidone and Belladonna. Infectious gastroenteritis/colitis [1A40] [62]
Amantadine DMS3YE9 Moderate Additive anticholinergic effects by the combination of Risperidone and Amantadine. Influenza [1E30-1E32] [95]
Berotralstat DMWA2DZ Moderate Decreased metabolism of Risperidone caused by Berotralstat mediated inhibition of CYP450 enzyme. Innate/adaptive immunodeficiency [4A00] [96]
Propiomazine DMKY8V1 Moderate Additive anticholinergic effects by the combination of Risperidone and Propiomazine. Insomnia [7A00-7A0Z] [62]
ITI-007 DMUQ1DO Moderate Additive anticholinergic effects by the combination of Risperidone and ITI-007. Insomnia [7A00-7A0Z] [62]
Polyethylene glycol DM4I1JP Moderate Increased risk of lowers seizure threshold by the combination of Risperidone and Polyethylene glycol. Irritable bowel syndrome [DD91] [61]
Phenolphthalein DM5SICT Moderate Increased risk of ventricular arrhythmias by the combination of Risperidone and Phenolphthalein. Irritable bowel syndrome [DD91] [61]
Clidinium DMUMQZ0 Moderate Additive anticholinergic effects by the combination of Risperidone and Clidinium. Irritable bowel syndrome [DD91] [62]
Dicyclomine DMZSDGX Moderate Additive anticholinergic effects by the combination of Risperidone and Dicyclomine. Irritable bowel syndrome [DD91] [62]
Physostigmine DM2N0TO Moderate Antagonize the effect of Risperidone when combined with Physostigmine. Lips/oral mucosa miscellaneous disorder [DA02] [68]
Glycerol phenylbutyrate DMDGRQO Moderate Decreased metabolism of Risperidone caused by Glycerol phenylbutyrate mediated inhibition of CYP450 enzyme. Liver disease [DB90-DB9Z] [64]
Crizotinib DM4F29C Major Increased risk of prolong QT interval by the combination of Risperidone and Crizotinib. Lung cancer [2C25] [97]
Ceritinib DMB920Z Major Increased risk of prolong QT interval by the combination of Risperidone and Ceritinib. Lung cancer [2C25] [61]
Dacomitinib DMOH8VY Moderate Decreased metabolism of Risperidone caused by Dacomitinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [98]
Osimertinib DMRJLAT Major Increased risk of prolong QT interval by the combination of Risperidone and Osimertinib. Lung cancer [2C25] [99]
Selpercatinib DMZR15V Major Increased risk of prolong QT interval by the combination of Risperidone and Selpercatinib. Lung cancer [2C25] [64]
Lumefantrine DM29GAD Major Increased risk of prolong QT interval by the combination of Risperidone and Lumefantrine. Malaria [1F40-1F45] [69]
Halofantrine DMOMK1V Major Increased risk of prolong QT interval by the combination of Risperidone and Halofantrine. Malaria [1F40-1F45] [100]
Hydroxychloroquine DMSIVND Major Increased risk of prolong QT interval by the combination of Risperidone and Hydroxychloroquine. Malaria [1F40-1F45] [101]
Primaquine DMWQ16I Moderate Increased risk of prolong QT interval by the combination of Risperidone and Primaquine. Malaria [1F40-1F45] [61]
Inotuzumab ozogamicin DMAC130 Moderate Increased risk of prolong QT interval by the combination of Risperidone and Inotuzumab ozogamicin. Malignant haematopoietic neoplasm [2B33] [64]
IPI-145 DMWA24P Moderate Decreased metabolism of Risperidone caused by IPI-145 mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [102]
Arsenic trioxide DM61TA4 Major Increased risk of ventricular arrhythmias by the combination of Risperidone and Arsenic trioxide. Mature B-cell lymphoma [2A85] [103]
Vemurafenib DM62UG5 Major Increased risk of prolong QT interval by the combination of Risperidone and Vemurafenib. Melanoma [2C30] [61]
LGX818 DMNQXV8 Moderate Increased risk of prolong QT interval by the combination of Risperidone and LGX818. Melanoma [2C30] [104]
Allopregnanolone DMNLHAC Moderate Additive CNS depression effects by the combination of Risperidone and Allopregnanolone. Mental/behavioural/neurodevelopmental disorder [6E20-6E8Z] [105]
Lasmiditan DMXLVDT Moderate Additive CNS depression effects by the combination of Risperidone and Lasmiditan. Migraine [8A80] [106]
Flibanserin DM70DTN Moderate Additive CNS depression effects by the combination of Risperidone and Flibanserin. Mood disorder [6A60-6E23] [107]
Panobinostat DM58WKG Major Increased risk of prolong QT interval by the combination of Risperidone and Panobinostat. Multiple myeloma [2A83] [108]
Thalidomide DM70BU5 Moderate Additive CNS depression effects by the combination of Risperidone and Thalidomide. Multiple myeloma [2A83] [109]
Siponimod DM2R86O Major Increased risk of ventricular arrhythmias by the combination of Risperidone and Siponimod. Multiple sclerosis [8A40] [69]
Fingolimod DM5JVAN Major Increased risk of ventricular arrhythmias by the combination of Risperidone and Fingolimod. Multiple sclerosis [8A40] [61]
Ozanimod DMT6AM2 Major Increased risk of ventricular arrhythmias by the combination of Risperidone and Ozanimod. Multiple sclerosis [8A40] [110]
Romidepsin DMT5GNL Moderate Increased risk of prolong QT interval by the combination of Risperidone and Romidepsin. Mycosis fungoides [2B01] [61]
Fedratinib DM4ZBK6 Moderate Decreased metabolism of Risperidone caused by Fedratinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [64]
Dasatinib DMJV2EK Moderate Increased risk of prolong QT interval by the combination of Risperidone and Dasatinib. Myeloproliferative neoplasm [2A20] [111]
Phenindamine DMDTC7R Moderate Additive anticholinergic effects by the combination of Risperidone and Phenindamine. Nasopharyngitis [CA00] [62]
Dimenhydrinate DM264B3 Moderate Additive anticholinergic effects by the combination of Risperidone and Dimenhydrinate. Nausea/vomiting [MD90] [62]
Promethazine DM6I5GR Moderate Additive anticholinergic effects by the combination of Risperidone and Promethazine. Nausea/vomiting [MD90] [62]
Rolapitant DM8XP26 Moderate Decreased metabolism of Risperidone caused by Rolapitant mediated inhibition of CYP450 enzyme. Nausea/vomiting [MD90] [112]
Cyclizine DM9G7BS Moderate Additive anticholinergic effects by the combination of Risperidone and Cyclizine. Nausea/vomiting [MD90] [62]
Dolasetron DMMG26Z Major Increased risk of prolong QT interval by the combination of Risperidone and Dolasetron. Nausea/vomiting [MD90] [61]
Ondansetron DMOTQ1I Moderate Increased risk of prolong QT interval by the combination of Risperidone and Ondansetron. Nausea/vomiting [MD90] [61]
Bupropion DM5PCS7 Major Decreased metabolism of Risperidone caused by Bupropion mediated inhibition of CYP450 enzyme. Nicotine use disorder [6C4A] [61]
Entrectinib DMMPTLH Moderate Increased risk of prolong QT interval by the combination of Risperidone and Entrectinib. Non-small cell lung cancer [2C25] [69]
Lorcaserin DMG6OYJ Moderate Increased risk of hyperprolactinemic effects by the combination of Risperidone and Lorcaserin. Obesity [5B80-5B81] [113]
Polythiazide DMCH80F Moderate Increased risk of ventricular arrhythmias by the combination of Risperidone and Polythiazide. Oedema [MG29] [69]
Levomethadyl Acetate DM06HG5 Major Increased risk of prolong QT interval by the combination of Risperidone and Levomethadyl Acetate. Opioid use disorder [6C43] [64]
Lofexidine DM1WXA6 Moderate Increased risk of prolong QT interval by the combination of Risperidone and Lofexidine. Opioid use disorder [6C43] [61]
Apraclonidine DMO4PVE Moderate Additive CNS depression effects by the combination of Risperidone and Apraclonidine. Optic nerve disorder [9C40] [114]
Rucaparib DM9PVX8 Moderate Increased risk of prolong QT interval by the combination of Risperidone and Rucaparib. Ovarian cancer [2C73] [61]
Oxymorphone DM65AGJ Major Additive CNS depression effects by the combination of Risperidone and Oxymorphone. Pain [MG30-MG3Z] [66]
Levorphanol DMGS80V Major Additive CNS depression effects by the combination of Risperidone and Levorphanol. Pain [MG30-MG3Z] [66]
Dezocine DMJDB0Y Major Additive CNS depression effects by the combination of Risperidone and Dezocine. Pain [MG30-MG3Z] [66]
Flavoxate DMKV4NL Moderate Additive anticholinergic effects by the combination of Risperidone and Flavoxate. Pain [MG30-MG3Z] [62]
Nalbuphine DMOSQGU Major Additive CNS depression effects by the combination of Risperidone and Nalbuphine. Pain [MG30-MG3Z] [66]
Buprenorphine DMPRI8G Major Additive CNS depression effects by the combination of Risperidone and Buprenorphine. Pain [MG30-MG3Z] [115]
Triclabendazole DMPWGBR Moderate Increased risk of prolong QT interval by the combination of Risperidone and Triclabendazole. Parasitic worm infestation [1F90] [61]
Pergolide DM14MAE Moderate Antagonize the effect of Risperidone when combined with Pergolide. Parkinsonism [8A00] [116]
Opicapone DM1BKA6 Moderate Antagonize the effect of Risperidone when combined with Opicapone. Parkinsonism [8A00] [116]
Biperiden DME78OA Moderate Antagonize the effect of Risperidone when combined with Biperiden. Parkinsonism [8A00] [88]
Levodopa DMN3E57 Moderate Antagonize the effect of Risperidone when combined with Levodopa. Parkinsonism [8A00] [116]
Pimavanserin DMR7IVC Moderate Increased risk of prolong QT interval by the combination of Risperidone and Pimavanserin. Parkinsonism [8A00] [117]
Orphenadrine DMW542E Moderate Additive anticholinergic effects by the combination of Risperidone and Orphenadrine. Parkinsonism [8A00] [62]
Abametapir DM2RX0I Moderate Decreased metabolism of Risperidone caused by Abametapir mediated inhibition of CYP450 enzyme. Pediculosis [1G00] [118]
Famotidine DMRL3AB Moderate Increased risk of prolong QT interval by the combination of Risperidone and Famotidine. Peptic ulcer [DA61] [69]
Macimorelin DMQYJIR Major Increased risk of prolong QT interval by the combination of Risperidone and Macimorelin. Pituitary gland disorder [5A60-5A61] [119]
Lefamulin DME6G97 Major Increased risk of prolong QT interval by the combination of Risperidone and Lefamulin. Pneumonia [CA40] [120]
Hydrocortisone DMGEMB7 Moderate Increased risk of ventricular arrhythmias by the combination of Risperidone and Hydrocortisone. Postoperative inflammation [1A00-CA43] [69]
Ritodrine DM4V6RL Moderate Increased risk of ventricular arrhythmias by the combination of Risperidone and Ritodrine. Preterm labour/delivery [JB00] [73]
Degarelix DM3O8QY Moderate Increased risk of prolong QT interval by the combination of Risperidone and Degarelix. Prostate cancer [2C82] [64]
ABIRATERONE DM8V75C Moderate Decreased metabolism of Risperidone caused by ABIRATERONE mediated inhibition of CYP450 enzyme. Prostate cancer [2C82] [121]
Enzalutamide DMGL19D Moderate Increased risk of prolong QT interval by the combination of Risperidone and Enzalutamide. Prostate cancer [2C82] [64]
Relugolix DMK7IWL Moderate Increased risk of prolong QT interval by the combination of Risperidone and Relugolix. Prostate cancer [2C82] [64]
Bicalutamide DMZMSPF Moderate Increased risk of prolong QT interval by the combination of Risperidone and Bicalutamide. Prostate cancer [2C82] [64]
Terazosin DM3JCVS Moderate Additive hypotensive effects by the combination of Risperidone and Terazosin. Prostate hyperplasia [GA90] [70]
Levomepromazine DMIKFEL Moderate Additive anticholinergic effects by the combination of Risperidone and Levomepromazine. Psychotic disorder [6A20-6A25] [62]
Tolazoline DMI40NL Moderate Additive hypotensive effects by the combination of Risperidone and Tolazoline. Pulmonary hypertension [BB01] [70]
Gatifloxacin DMSL679 Major Increased risk of prolong QT interval by the combination of Risperidone and Gatifloxacin. Respiratory infection [CA07-CA4Z] [122]
Neupro DMHEAB1 Moderate Antagonize the effect of Risperidone when combined with Neupro. Restless legs syndrome [7A80] [116]
Fentanyl DM8WAHT Major Additive CNS depression effects by the combination of Risperidone and Fentanyl. Sensation disturbance [MB40] [66]
Vardenafil DMTBGW8 Moderate Increased risk of prolong QT interval by the combination of Risperidone and Vardenafil. Sexual dysfunction [HA00-HA01] [61]
Larotrectinib DM26CQR Moderate Decreased metabolism of Risperidone caused by Larotrectinib mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [69]
LEE011 DMMX75K Major Increased risk of prolong QT interval by the combination of Risperidone and LEE011. Solid tumour/cancer [2A00-2F9Z] [61]
Vandetanib DMRICNP Major Increased risk of prolong QT interval by the combination of Risperidone and Vandetanib. Solid tumour/cancer [2A00-2F9Z] [61]
Triptorelin DMTK4LS Moderate Increased risk of prolong QT interval by the combination of Risperidone and Triptorelin. Solid tumour/cancer [2A00-2F9Z] [64]
Doxorubicin DMVP5YE Moderate Increased risk of prolong QT interval by the combination of Risperidone and Doxorubicin. Solid tumour/cancer [2A00-2F9Z] [61]
Pitolisant DM8RFNJ Moderate Increased risk of prolong QT interval by the combination of Risperidone and Pitolisant. Somnolence [MG42] [61]
Telavancin DM58VQX Moderate Increased risk of prolong QT interval by the combination of Risperidone and Telavancin. Staphylococcal/streptococcal disease [1B5Y] [61]
Fostamatinib DM6AUHV Moderate Decreased metabolism of Risperidone caused by Fostamatinib mediated inhibition of CYP450 enzyme. Thrombocytopenia [3B64] [123]
Lenvatinib DMB1IU4 Moderate Increased risk of prolong QT interval by the combination of Risperidone and Lenvatinib. Thyroid cancer [2D10] [61]
Cabozantinib DMIYDT4 Major Increased risk of prolong QT interval by the combination of Risperidone and Cabozantinib. Thyroid cancer [2D10] [64]
Papaverine DMCA9QP Moderate Additive hypotensive effects by the combination of Risperidone and Papaverine. Tonus and reflex abnormality [MB47] [70]
Tacrolimus DMZ7XNQ Moderate Increased risk of prolong QT interval by the combination of Risperidone and Tacrolimus. Transplant rejection [NE84] [61]
Chlorpheniramine DM5URA2 Moderate Additive anticholinergic effects by the combination of Risperidone and Chlorpheniramine. Vasomotor/allergic rhinitis [CA08] [62]
Methdilazine DMAUHQX Moderate Additive anticholinergic effects by the combination of Risperidone and Methdilazine. Vasomotor/allergic rhinitis [CA08] [62]
Carbinoxamine DMCT31R Moderate Additive anticholinergic effects by the combination of Risperidone and Carbinoxamine. Vasomotor/allergic rhinitis [CA08] [62]
Trimeprazine DMEMV9D Moderate Additive anticholinergic effects by the combination of Risperidone and Trimeprazine. Vasomotor/allergic rhinitis [CA08] [67]
Brompheniramine DMFOVSD Moderate Additive anticholinergic effects by the combination of Risperidone and Brompheniramine. Vasomotor/allergic rhinitis [CA08] [62]
Acrivastine DMTIGA0 Moderate Additive anticholinergic effects by the combination of Risperidone and Acrivastine. Vasomotor/allergic rhinitis [CA08] [62]
Procainamide DMNMXR8 Major Increased risk of prolong QT interval by the combination of Risperidone and Procainamide. Ventricular tachyarrhythmia [BC71] [61]
Propafenone DMPIBJK Moderate Increased risk of prolong QT interval by the combination of Risperidone and Propafenone. Ventricular tachyarrhythmia [BC71] [61]
Flecainide DMSQDLE Moderate Increased risk of prolong QT interval by the combination of Risperidone and Flecainide. Ventricular tachyarrhythmia [BC71] [61]
Amiodarone DMUTEX3 Major Increased risk of prolong QT interval by the combination of Risperidone and Amiodarone. Ventricular tachyarrhythmia [BC71] [61]
⏷ Show the Full List of 227 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Acesulfame E00341 36573 Flavoring agent
Allura red AC dye E00338 33258 Colorant
Aminoethanoic acid E00025 750 Buffering agent; Disintegrant; Lyophilization aid
Aspartame E00402 134601 Flavoring agent
Calcium carbonate E00198 10112 Binding agent; Buffering agent; Diluent; Opacifying agent
D&C brown no. 1 E00565 23675104 Colorant
D&C green no. 5 E00265 20431 Colorant
Docusate sodium E00563 23673837 Surfactant
FD&C blue no. 1 E00263 19700 Colorant
FD&C blue no. 2 E00446 2723854 Colorant
Hydrazine yellow E00409 164825 Colorant
Mannitol E00103 6251 Diluent; Flavoring agent; Lyophilization aid; Plasticizing agent; Tonicity agent
Menthol E00050 1254 Flavoring agent
Monoammonium glycyrrhizate E00352 62074 Emulsifying agent; Flavoring agent
Pigment orange 2 E00379 80852 Colorant
Pigment yellow 3 E00388 94326 Colorant
Quinoline yellow WS E00309 24671 Colorant
Sodium benzoate E00432 517055 Antimicrobial preservative; lubricant
Sodium lauryl sulfate E00464 3423265 Emulsifying agent; Modified-release agent; Penetration agent; Solubilizing agent; Surfactant; lubricant
Sodium stearyl fumarate E00545 23665634 lubricant
Stearic acid E00079 5281 Emulsifying agent; Solubilizing agent; Viscosity-controlling agent; lubricant
Sunset yellow FCF E00255 17730 Colorant
Beta-D-lactose E00099 6134 Diluent; Dry powder inhaler carrier; Lyophilization aid
Calcium stearate E00244 15324 lubricant
Calcium sulfate anhydrous E00303 24497 Desiccant; Diluent
Carmellose sodium E00625 Not Available Disintegrant
Crospovidone E00626 Not Available Disintegrant
Dextrin E00359 62698 Binding agent; Diluent; Microencapsulating agent; Stiffening agent; Suspending agent; Viscosity-controlling agent
Eisenoxyd E00585 56841934 Colorant
Ferric hydroxide oxide yellow E00539 23320441 Colorant
Ferrosoferric oxide E00231 14789 Colorant
Hexahydric alcohol E00083 5780 Diluent; Flavoring agent; Humectant; Plasticizing agent
Hypromellose E00634 Not Available Coating agent
Lactose monohydrate E00393 104938 Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium carbonate E00205 11029 Adsorbent; Diluent
Magnesium stearate E00208 11177 lubricant
Polyethylene glycol 3350 E00652 Not Available Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polyethylene glycol 400 E00653 Not Available Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polyethylene glycol 6000 E00655 Not Available Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polyvinyl alcohol E00666 Not Available Coating agent; Emulsion stabilizing agent; Film/Membrane-forming agent
Propylene glycol E00040 1030 Antimicrobial preservative; Humectant; Plasticizing agent; Solvent
Saccharose E00091 5988 Binding agent; Coating agent; Cryoprotectant; Diluent; Flavoring agent; Suspending agent; Viscosity-controlling agent
Silicon dioxide E00670 Not Available Anticaking agent; Opacifying agent; Viscosity-controlling agent
Sodium chloride E00077 5234 Diluent; Tonicity agent
Sodium hydroxide E00234 14798 Alkalizing agent
Talc E00520 16211421 Anticaking agent; Diluent; Glidant; lubricant
Tartaric acid E00029 875 Acidulant; Complexing agent; Flavoring agent
Titanium dioxide E00322 26042 Coating agent; Colorant; Opacifying agent
Triacetin E00080 5541 Humectant; Plasticizing agent; Solvent
⏷ Show the Full List of 49 Pharmaceutical Excipients of This Drug
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Risperidone 0.25 mg tablet 0.25 mg Disintegrating Oral Tablet Oral
Risperidone 2 mg tablet 2 mg Oral Tablet Oral
Risperidone 0.5 mg tablet 0.5 mg Disintegrating Oral Tablet Oral
Risperidone 1 mg tablet 1 mg Disintegrating Oral Tablet Oral
Risperidone 2 mg tablet 2 mg Disintegrating Oral Tablet Oral
Risperidone 3 mg tablet 3 mg Disintegrating Oral Tablet Oral
Risperidone 4 mg tablet 4 mg Disintegrating Oral Tablet Oral
Risperidone 0.25 mg tablet 0.25 mg Oral Tablet Oral
Risperidone 0.5 mg tablet 0.5 mg Oral Tablet Oral
Risperidone 1 mg tablet 1 mg Oral Tablet Oral
Risperidone 4 mg tablet 4 mg Oral Tablet Oral
Risperidone 3 mg tablet 3 mg Oral Tablet Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 96).
2 Emerging anxiolytics. Expert Opin Emerg Drugs. 2007 Nov;12(4):541-54.
3 Phentermine and topiramate extended-release: a new treatment for obesity and its role in a complications-centric approach to obesity medical management. Expert Opin Drug Saf. 2013 Sep;12(5):741-56. doi: 10.1517/14740338.2013.806481. Epub 2013 Jun 6.
4 BDDCS applied to over 900 drugs
5 Critical Evaluation of Human Oral Bioavailability for Pharmaceutical Drugs by Using Various Cheminformatics Approaches
6 Pharmacokinetics of Risperidone: Clinical Summary
7 Plasma protein binding of risperidone and its distribution in blood. Psychopharmacology (Berl). 1994 May;114(4):566-72.
8 Takahiro M, Haruo I, Toshihiko, I: Identification of Gemfibrozil Metabolites, Produced as Positional Isomers in Human Liver Microsomes, by On-line Analyses Using Liquid Chromatography/Mass Spectrometry and Liquid Chromatography/Nuclear Magnetic Resonance Spectroscopy J. Mass Spectrom. Soc. Jpn.. 2004 Jun 6;52(5):277-283.
9 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
10 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
11 FDA Approved Drug Products: Risperdal (risperidone) for oral use
12 Randomized clinical comparison of perospirone and risperidone in patients with schizophrenia: Kansai Psychiatric Multicenter Study. Psychiatry Clin Neurosci. 2009 Jun;63(3):322-8.
13 Upcoming agents for the treatment of schizophrenia: mechanism of action, efficacy and tolerability. Drugs. 2008;68(16):2269-92.
14 Effect of verapamil on pharmacokinetics and pharmacodynamics of risperidone: in vivo evidence of involvement of P-glycoprotein in risperidone disposition. Clin Pharmacol Ther. 2005 Jul;78(1):43-51.
15 Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
16 Cytochrome P450 3A inhibitor itraconazole affects plasma concentrations of risperidone and 9-hydroxyrisperidone in schizophrenic patients. Clin Pharmacol Ther. 2005 Nov;78(5):520-8.
17 Different enantioselective 9-hydroxylation of risperidone by the two human CYP2D6 and CYP3A4 enzymes. Drug Metab Dispos. 2001 Oct;29(10):1263-8.
18 Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
19 Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
20 Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
21 Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
22 Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
23 Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
24 Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
25 The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1994 Jul 19;48(2):267-76.
26 Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
27 Inhibitory effects of anticancer drugs on dextromethorphan-O-demethylase activity in human liver microsomes. Cancer Chemother Pharmacol. 1993;32(6):491-5.
28 Effect of genetic polymorphism on the metabolism of endogenous neuroactive substances, progesterone and p-tyramine, catalyzed by CYP2D6. Brain Res Mol Brain Res. 2004 Oct 22;129(1-2):117-23.
29 CYP2D6 polymorphisms and tamoxifen metabolism: clinical relevance. Curr Oncol Rep. 2010 Jan;12(1):7-15.
30 Inhibition of cytochrome P450 2D6: structure-activity studies using a series of quinidine and quinine analogues. Chem Res Toxicol. 2003 Apr;16(4):450-9.
31 Effects of propofol on human hepatic microsomal cytochrome P450 activities. Xenobiotica. 1998 Sep;28(9):845-53.
32 Pharmacogenetics of schizophrenia. Am J Med Genet. 2000 Spring;97(1):98-106.
33 Roles of CYP2A6 and CYP2B6 in nicotine C-oxidation by human liver microsomes. Arch Toxicol. 1999 Mar;73(2):65-70.
34 Structure-activity relationship for human cytochrome P450 substrates and inhibitors. Drug Metab Rev. 2002 Feb-May;34(1-2):69-82.
35 Drug related genetic polymorphisms affecting adverse reactions to methotrexate, vinblastine, doxorubicin and cisplatin in patients with urothelial cancer. J Urol. 2008 Dec;180(6):2389-95.
36 Human prostate CYP3A5: identification of a unique 5'-untranslated sequence and characterization of purified recombinant protein. Biochem Biophys Res Commun. 1999 Jul 14;260(3):676-81.
37 Polymorphisms in cytochrome P4503A5 (CYP3A5) may be associated with race and tumor characteristics, but not metabolism and side effects of tamoxifen in breast cancer patients. Cancer Lett. 2005 Jan 10;217(1):61-72.
38 Drug Interactions Flockhart Table
39 Induction of hepatic CYP2E1 by a subtoxic dose of acetaminophen in rats: increase in dichloromethane metabolism and carboxyhemoglobin elevation. Drug Metab Dispos. 2007 Oct;35(10):1754-8.
40 Urinary 6 beta-hydroxycortisol excretion in rheumatoid arthritis. Br J Rheumatol. 1997 Jan;36(1):54-8.
41 Clinical pharmacokinetics of imatinib. Clin Pharmacokinet. 2005;44(9):879-94.
42 Kinetics and regulation of cytochrome P450-mediated etoposide metabolism. Drug Metab Dispos. 2004 Sep;32(9):993-1000.
43 Differential mechanism-based inhibition of CYP3A4 and CYP3A5 by verapamil. Drug Metab Dispos. 2005 May;33(5):664-71.
44 Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
45 MDR1 (ABCB1) G1199A (Ser400Asn) polymorphism alters transepithelial permeability and sensitivity to anticancer agents. Cancer Chemother Pharmacol. 2009 Jun;64(1):183-8.
46 Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
47 Folate transporter expression decreases in the human placenta throughout pregnancy and in pre-eclampsia. Pregnancy Hypertens. 2012 Apr;2(2):123-31.
48 Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein. Pharm Res. 2001 Dec;18(12):1660-8.
49 Antiestrogens and steroid hormones: substrates of the human P-glycoprotein. Biochem Pharmacol. 1994 Jul 19;48(2):287-92.
50 Association of genetic polymorphisms in the influx transporter SLCO1B3 and the efflux transporter ABCB1 with imatinib pharmacokinetics in patients with chronic myeloid leukemia. Ther Drug Monit. 2011 Apr;33(2):244-50.
51 The Detection of Dopamine Gene Receptors (DRD1-DRD5) Expression on Human Peripheral Blood Lymphocytes by Real Time PCR. Iran J Allergy Asthma Immunol. 2004 Dec;3(4):169-74.
52 Dopaminergic synapses in the matrix of the ventrolateral striatum after chronic haloperidol treatment. Synapse. 2002 Aug;45(2):78-85.
53 CYP2D6 and DRD2 genes differentially impact pharmacodynamic sensitivity and time course of prolactin response to perphenazine. Pharmacogenet Genomics. 2007 Nov;17(11):989-93.
54 Synthesis and in vitro binding of N-phenyl piperazine analogs as potential dopamine D3 receptor ligands. Bioorg Med Chem. 2005 Jan 3;13(1):77-87.
55 Screening of domperidone in wastewater by high performance liquid chromatography and solid phase extraction methods. Talanta. 2006 Jan 15;68(3):928-31.
56 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 3639).
57 Receptor reserve-dependent properties of antipsychotics at human dopamine D2 receptors. Eur J Pharmacol. 2009 Apr 1;607(1-3):35-40.
58 [The benzamides tiapride, sulpiride, and amisulpride in treatment for Tourette's syndrome]. Nervenarzt. 2007 Mar;78(3):264, 266-8, 270-1.
59 Modulatory role of dopamine D2 receptors and fundamental role of L-type Ca2+ channels in the induction of long-term potentiation in the basolateral... Eur J Pharmacol. 2009 Mar 15;606(1-3):90-3.
60 Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
61 Canadian Pharmacists Association.
62 Cohen MA, Alfonso CA, Mosquera M. Development of urinary retention during treatment with clozapine and meclizine [published correction appears in Am J Psychiatry 1994 Jun;151(6):952]. Am J Psychiatry. 1994;151(4):619-620. [PMID: 8147469]
63 Product Information. Barhemsys (amisulpride). Acacia Pharma, Inc, Indianapolis, IN.
64 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
65 Product Information. Tibsovo (ivosidenib). Agios Pharmaceuticals, Cambridge, MA.
66 US Food and Drug Administration "FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines requires its strongest warning.".
67 Kulik AV, Wilbur R "Delirium and stereotypy from anticholinergic antiparkinson drugs." Prog Neuropsychopharmacol Biol Psychiatry 6 (1982): 75-82. [PMID: 7202232]
68 Beers MH, Ouslander JG, Rollingher I, Reuben DB, Brooks J, Beck JC "Explicit criteria for determining inappropriate medication use in nursing home residents." Arch Intern Med 151 (1991): 1825-32. [PMID: 1888249]
69 Cerner Multum, Inc. "Australian Product Information.".
70 Aronowitz JS, Chakos MH, Safferman AZ, Lieberman JA "Syncope associated with the combination of clozapine and enalapril." J Clin Psychopharmacol 14 (1994): 429-30. [PMID: 7884028]
71 Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ.
72 Product Information. Arcapta Neohaler (indacaterol). Novartis Pharmaceuticals, East Hanover, NJ.
73 Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32. [PMID: 7042176]
74 Ball P "Quinolone-induced QT interval prolongation: a not-so-unexpected class effect." J Antimicrob Chemother 45 (2000): 557-9. [PMID: 10797074]
75 Eronen M, Putkonen H, Hallikainen T, Vartiainen H "Lethal gastroenteritis associated with clozapine and loperamide." Am J Psychiatry 160 (2003): 2242-2243. [PMID: 14638602]
76 Multum Information Services, Inc. Expert Review Panel.
77 Product Information. Daurismo (glasdegib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
78 Cole JM, Sheehan AH, Jordan JK "Concomitant use of ipratropium and tiotropium in chronic obstructive plmonary disease." Ann Pharmacother 46 (2012): 1717-21. [PMID: 23170031]
79 US Food and Drug Administration "FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines requires its strongest warning.".
80 Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7. [PMID: 3725002]
81 Hanci V, Aydin M, Yurtlu BS, et.al "Anesthesia induction with sevoflurane and propofol: evaluation of P-wave dispersion, QT and corrected QT intervals." Kaohsiung J Med Sci 26 (2010): 470-7. [PMID: 20837343]
82 Product Information. Lamprene (clofazimine). Novartis Pharmaceuticals, East Hanover, NJ.
83 Johnson AL, Hollister LE, Berger PA "The anticholinergic intoxication syndrome: diagnosis and treatment." J Clin Psychiatry 42 (1981): 313-7. [PMID: 7251568]
84 Burke RE, Fahn S, Mayeux R, Weinberg H, Louis K, Willner JH "Neuroleptic malignant syndrome caused by dopamine-depleting drugs in a patient with Huntington disease." Neurology 31 (1981): 1022-5. [PMID: 6115336]
85 Product Information. Austedo (deutetrabenazine). Teva Pharmaceuticals USA, North Wales, PA.
86 Product Information. Ingrezza (valbenazine). Neurocrine Biosciences, Inc., San Diego, CA.
87 Product Information. Zonegran (zonisamide) Elan Pharmaceuticals, S. San Francisco, CA.
88 Hvizdos AJ, Bennett JA, Wells BG, Rappaport KB, Mendel SA "Anticholinergic psychosis in a patient receiving usual doses of haloperidol." Clin Pharm 2 (1983): 174-8. [PMID: 6883947]
89 Product Information. Myrbetriq (mirabegron). Astellas Pharma US, Inc, Deerfield, IL.
90 AbdelRahman SM, Gotschall RR, Kauffman RE, Leeder JS, Kearns GL "Investigation of terbinafine as a CYP2D6 inhibitor in vivo." Clin Pharmacol Ther 65 (1999): 465-72. [PMID: 10340911]
91 Product Information. Rukobia (fostemsavir). ViiV Healthcare, Research Triangle Park, NC.
92 Product Information. Stribild (cobicistat/elvitegravir/emtricitabine/tenofov). Gilead Sciences, Foster City, CA.
93 Anson BD, Weaver JG, Ackerman MJ, et al. "Blockade of HERG channels by HIV protease inhibitors." Lancet 365 (2005): 682-686. [PMID: 15721475]
94 Product Information. Givlaari (givosiran). Alnylam Pharmaceuticals, Cambridge, MA.
95 Postma JU, van Tilburg W "Visual hallucinations and delirium during treatment with amantadine (Symmetrel)." J Am Geriatr Soc 23 (1975): 212-5. [PMID: 123540]
96 Product Information. Orladeyo (berotralstat). BioCryst Pharmaceuticals Inc, Durham, NC.
97 Product Information. Xalkori (crizotinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
98 Product Information. Vizimpro (dacomitinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
99 Product Information. Tagrisso (osimertinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
100 Abernethy DR, Wesche DL, Barbey JT, et al. "Stereoselective halofantrine disposition and effect: concentration-related QTc prolongation." Br J Clin Pharmacol 51 (2001): 231-7. [PMID: 11298069]
101 Harper KM, Knapp DJ, Criswell HE, Breese GR "Vasopressin and alcohol: A multifaceted relationship." Psychopharmacology (Berl) 235 (2018): 3363-79. [PMID: 32936259]
102 Product Information. Copiktra (duvelisib). Verastem, Inc., Needham, MA.
103 Ohnishi K, Yoshida H, Shigeno K, et al. "Prolongation of the QT interval and ventricular tachycardia in patients treated with arsenic trioxide for acute promyelocytic leukemia." Ann Intern Med 133 (2000): 881-5. [PMID: 11103058]
104 Product Information. Braftovi (encorafenib). Array BioPharma Inc., Boulder, CO.
105 Product Information. Zulresso (brexanolone). Sage Therapeutics, Inc., Cambridge, MA.
106 Product Information. Reyvow (lasmiditan). Lilly, Eli and Company, Indianapolis, IN.
107 Product Information. Addyi (flibanserin). Sprout Pharmaceuticals, Raleigh, NC.
108 Product Information. Farydak (panobinostat). Novartis Pharmaceuticals, East Hanover, NJ.
109 Product Information. Thalomid (thalidomide). Celgene Corporation, Warren, NJ.
110 Product Information. Zeposia (ozanimod). Celgene Corporation, Summit, NJ.
111 Product Information. Sprycel (dasatinib). Bristol-Myers Squibb, Princeton, NJ.
112 Product Information. Varubi (rolapitant). Tesaro Inc., Waltham, MA.
113 Product Information. Belviq (lorcaserin). Eisai Inc, Teaneck, NJ.
114 Product Information. Alphagan (brimonidine ophthalmic). Allergan Inc, Irvine, CA.
115 Sekar M, Mimpriss TJ "Buprenorphine, benzodiazepines and prolonged respiratory depression." Anaesthesia 42 (1987): 567-8. [PMID: 3592200]
116 Mims RB, Scott CL, Modebe O, Bethune JE "Inhibition of L-dopa-induced growth hormone stimulation by pyridoxine and chlorpromazine." J Clin Endocrinol Metab 40 (1975): 256-9. [PMID: 1117978]
117 Product Information. Nuplazid (pimavanserin). Accelis Pharma, East Windsor, NJ.
118 Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
119 Product Information. Macrilen (macimorelin). Aeterna Zentaris, Charleston, SC.
120 Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
121 Product Information. Zytiga (abiraterone). Centocor Inc, Malvern, PA.
122 Ansari SR, Chopra N "Gatifloxacin and Prolonged QT Interval." Am J Med Sci 327 (2004): 55-6. [PMID: 14722399]
123 Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.